{"id":"tgr-1202","safety":{"commonSideEffects":[{"rate":"30-40%","effect":"Neutropenia"},{"rate":"20-30%","effect":"Thrombocytopenia"},{"rate":"20-30%","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting PI3K delta, TGR-1202 disrupts the signaling pathways that promote the survival and proliferation of cancer cells. This leads to the induction of apoptosis and inhibition of tumor growth. Additionally, TGR-1202 has been shown to enhance the anti-tumor activity of other therapies.","oneSentence":"TGR-1202 is a selective inhibitor of the PI3K delta subunit.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:38:21.410Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory B-cell malignancies"}]},"trialDetails":[{"nctId":"NCT03269669","phase":"PHASE2","title":"Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-01-23","conditions":"Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma","enrollment":73},{"nctId":"NCT03919175","phase":"PHASE2","title":"Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2019-09-01","conditions":"Lymphoma, Follicular Lymphoma, Follicular Lymphoma, Grade 1","enrollment":18},{"nctId":"NCT04163718","phase":"PHASE2","title":"TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-11-12","conditions":"Chronic Lymphocytic Leukemia","enrollment":12},{"nctId":"NCT03283137","phase":"PHASE1","title":"Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2018-01-23","conditions":"CLL, B-cell Non Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT02612311","phase":"PHASE3","title":"Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia","status":"TERMINATED","sponsor":"TG Therapeutics, Inc.","startDate":"2015-11-19","conditions":"Chronic Lymphocytic Leukemia","enrollment":603},{"nctId":"NCT04783415","phase":"PHASE2","title":"Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-03-26","conditions":"Mantle Cell Lymphoma","enrollment":12},{"nctId":"NCT02268851","phase":"PHASE1","title":"A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2014-11","conditions":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma","enrollment":45},{"nctId":"NCT03671590","phase":"PHASE1","title":"Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies","status":"TERMINATED","sponsor":"TG Therapeutics, Inc.","startDate":"2018-09-10","conditions":"Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia","enrollment":172},{"nctId":"NCT02742090","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy","status":"TERMINATED","sponsor":"TG Therapeutics, Inc.","startDate":"2016-04-21","conditions":"Chronic Lymphocytic Leukemia","enrollment":51},{"nctId":"NCT02493530","phase":"PHASE1","title":"TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea","status":"COMPLETED","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2015-07","conditions":"Myelofibrosis, Polycythemia Vera","enrollment":60},{"nctId":"NCT03801525","phase":"PHASE2, PHASE3","title":"Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)","status":"TERMINATED","sponsor":"TG Therapeutics, Inc.","startDate":"2019-05-16","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":277},{"nctId":"NCT02874404","phase":"PHASE2","title":"TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2016-10-07","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":13},{"nctId":"NCT04692155","phase":"PHASE1, PHASE2","title":"Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL)","status":"TERMINATED","sponsor":"University of Alabama at Birmingham","startDate":"2021-08-31","conditions":"Mantle Cell Lymphoma","enrollment":1},{"nctId":"NCT04016805","phase":"PHASE2","title":"Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax","status":"TERMINATED","sponsor":"TG Therapeutics, Inc.","startDate":"2019-08-05","conditions":"Chronic Lymphocytic Leukemia","enrollment":41},{"nctId":"NCT03828448","phase":"PHASE2","title":"Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma","status":"TERMINATED","sponsor":"TG Therapeutics, Inc.","startDate":"2019-07-10","conditions":"Follicular Lymphoma, Small Lymphocytic Lymphoma","enrollment":34},{"nctId":"NCT03364231","phase":"PHASE2","title":"Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"TG Therapeutics, Inc.","startDate":"2017-11-30","conditions":"Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Non Follicular Indolent Non-Hodgkin Lymphoma","enrollment":21},{"nctId":"NCT02656303","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304","status":"TERMINATED","sponsor":"TG Therapeutics, Inc.","startDate":"2016-01-07","conditions":"Chronic Lymphocytic Leukemia","enrollment":116},{"nctId":"NCT04149821","phase":"PHASE2","title":"Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2021-02-10","conditions":"Chronic Lymphocytic Leukemia, CLL Progression, CLL/SLL","enrollment":1},{"nctId":"NCT05152459","phase":"PHASE1, PHASE2","title":"Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma","status":"WITHDRAWN","sponsor":"City of Hope Medical Center","startDate":"2023-05-01","conditions":"Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma","enrollment":""},{"nctId":"NCT03776864","phase":"PHASE2","title":"Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma","status":"TERMINATED","sponsor":"University of Washington","startDate":"2019-09-26","conditions":"Hodgkin's Lymphoma","enrollment":6},{"nctId":"NCT02535286","phase":"PHASE1","title":"Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation","status":"COMPLETED","sponsor":"TG Therapeutics, Inc.","startDate":"2015-09-18","conditions":"Chronic Lymphocytic Leukemia, Richter Syndrome","enrollment":27},{"nctId":"NCT04635683","phase":"PHASE1","title":"Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma","status":"WITHDRAWN","sponsor":"Yazeed Sawalha","startDate":"2022-09-30","conditions":"Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Follicular Lymphoma","enrollment":""},{"nctId":"NCT03379051","phase":"PHASE1, PHASE2","title":"Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL","status":"TERMINATED","sponsor":"TG Therapeutics, Inc.","startDate":"2018-03-27","conditions":"Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma","enrollment":78},{"nctId":"NCT02793583","phase":"PHASE2, PHASE3","title":"Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma","status":"TERMINATED","sponsor":"TG Therapeutics, Inc.","startDate":"2016-05-25","conditions":"Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma","enrollment":710},{"nctId":"NCT03207256","phase":"PHASE2","title":"Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials","status":"TERMINATED","sponsor":"TG Therapeutics, Inc.","startDate":"2017-08-09","conditions":"Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma","enrollment":51},{"nctId":"NCT01767766","phase":"PHASE1","title":"Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies","status":"COMPLETED","sponsor":"TG Therapeutics, Inc.","startDate":"2013-01-07","conditions":"Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Peripheral T-Cell Lymphoma","enrollment":90},{"nctId":"NCT02867618","phase":"PHASE1, PHASE2","title":"Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma","status":"TERMINATED","sponsor":"Columbia University","startDate":"2016-10-16","conditions":"Hodgkin Disease, Lymphoma, Non-hodgkin","enrollment":14},{"nctId":"NCT03178201","phase":"PHASE2","title":"TGR1202 in Relapsed and Refractory Follicular Lymphoma","status":"TERMINATED","sponsor":"Columbia University","startDate":"2017-08-20","conditions":"Follicular Lymphoma","enrollment":5},{"nctId":"NCT02006485","phase":"PHASE1","title":"Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies","status":"COMPLETED","sponsor":"TG Therapeutics, Inc.","startDate":"2013-12-13","conditions":"Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma","enrollment":160},{"nctId":"NCT02574663","phase":"PHASE1","title":"TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors","status":"COMPLETED","sponsor":"TG Therapeutics, Inc.","startDate":"2015-09-11","conditions":"Pancreatic Cancer, Colorectal Cancer, Rectal Cancer","enrollment":66},{"nctId":"NCT02100852","phase":"PHASE1","title":"TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)","status":"COMPLETED","sponsor":"TG Therapeutics, Inc.","startDate":"2014-03-12","conditions":"Chronic Lymphocytic Leukemia","enrollment":19},{"nctId":"NCT02164006","phase":"PHASE1","title":"Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients","status":"COMPLETED","sponsor":"TG Therapeutics, Inc.","startDate":"2014-06-11","conditions":"Hodgkin's Lymphoma","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["formerly as RP5307","RP5264","Umbralisib","umbralisib","(formerly) RP-5264"],"phase":"phase_3","status":"active","brandName":"TGR-1202","genericName":"TGR-1202","companyName":"Vanderbilt-Ingram Cancer Center","companyId":"vanderbilt-ingram-cancer-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TGR-1202 is a selective inhibitor of the PI3K delta subunit. Used for Relapsed or refractory B-cell malignancies.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}